29 related articles for article (PubMed ID: 22266083)
1. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.
Kampmann C; Perrin A; Beck M
Orphanet J Rare Dis; 2015 Sep; 10():125. PubMed ID: 26416388
[TBL] [Abstract][Full Text] [Related]
2. Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey.
Barba-Romero MÁ; Pintos-Morell G
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27886142
[TBL] [Abstract][Full Text] [Related]
3. Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS).
Barba-Romero MÁ; Rivera-Gallego A; Pintos-Morell G;
Int J Clin Pract; 2011 Aug; 65(8):903-10. PubMed ID: 21679285
[TBL] [Abstract][Full Text] [Related]
4. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.
Wilcox WR; Oliveira JP; Hopkin RJ; Ortiz A; Banikazemi M; Feldt-Rasmussen U; Sims K; Waldek S; Pastores GM; Lee P; Eng CM; Marodi L; Stanford KE; Breunig F; Wanner C; Warnock DG; Lemay RM; Germain DP;
Mol Genet Metab; 2008 Feb; 93(2):112-28. PubMed ID: 18037317
[TBL] [Abstract][Full Text] [Related]
5. Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry.
Politei JM; Cabrera G; Amartino H; Valdez R; Masllorens F; Ripeau D; Antongiovanni N; Soliani A; Luna P; Cedrolla M; Fernandez S; Fainboim A
Int J Clin Pract; 2013 Jan; 67(1):66-72. PubMed ID: 23241050
[TBL] [Abstract][Full Text] [Related]
6. Demographic characterization of Brazilian patients enrolled in the Fabry Registry.
Martins AM; Kyosen SO; Garrote J; Marques FM; Guilhem JG; Macedo E; Sobral Neto J; Ura S
Genet Mol Res; 2013 Jan; 12(1):136-42. PubMed ID: 23408399
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of patients with Fabry disease in Argentina].
AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of patients from a Spanish Registry of Fabry disease in two periods].
Barba Romero MÁ; Rivera Gallego A; Pintos Morell G;
Med Clin (Barc); 2012 Oct; 139(9):379-84. PubMed ID: 22266083
[TBL] [Abstract][Full Text] [Related]
9. [Neurological complications of Fabry-disease].
Vastagh I; Constantin T; Kéri A; Rudas G; Fekete G; Bereczki D
Ideggyogy Sz; 2011 Jan; 64(1-2):29-35. PubMed ID: 21428036
[TBL] [Abstract][Full Text] [Related]
10. Fabry disease.
Tarabuso AL
Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
[TBL] [Abstract][Full Text] [Related]
11. [Cardiological follow-up in patients with Fabry disease].
Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
[TBL] [Abstract][Full Text] [Related]
12. Interdisciplinary approach towards female patients with Fabry disease.
Weidemann F; Niemann M; Sommer C; Beer M; Breunig F; Wanner C
Eur J Clin Invest; 2012 Apr; 42(4):455-62. PubMed ID: 22049975
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
